EUVIMEDEUVIMED entdecken
Crossref

Lenvatinib inhibits cholangiocarcinoma progression by targeting the FGF19/PI3K/AKT signaling pathway

Yingcheng Wei, Lei Yang, Chenwei Tang, Hongkai Zhuang, Xinming Chen, Xiaowu Ma, Xuesong Deng, Yajin Chen, Wenliang Tan, Changzhen Shang

Apoptosis · 2025-02 · 30 (1-2) · 185-196

DOI: 10.1007/s10495-024-02028-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Apoptosis, online erschienen am 10.11.2024. Verfasst von Yingcheng Wei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangz…. Hauptthemen laut MEDLINE: Quinolines, Phenylurea Compounds, Proto-Oncogene Proteins c-akt, Signal Transduction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Guangzhou Municipal Science and Technology Project, National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cholangiocarcinoma (CCA) is known for its high aggressiveness and dismal prognosis, whose effectiveness of systemic therapy remains limited. As a multi-target drug, lenvatinib has exhibited promising effects in many solid tumors. However, the therapeutic role of lenvatinib in CCA is rarely investigated. Here, the in vitro assays including EdU, colony formation, transwell, wound healing, and apoptosis analyses demonstrated that lenvatinib significantly inhibited the proliferation, migration, and invasion, while simultaneously inducing apoptosis of CCA cells. Mechanistically, lenvatinib downregulated the expression of FGF19 and inactivated the PI3K/AKT signaling pathway. Depletion of FGF19 enhanced the anti-tumor effects of lenvatinib, which was attributed to the inhibition of p-PI3K and p-AKT expression in CCA cells. In contrast, overexpression of FGF19 activated the PI3K/AKT signaling pathway, thereby impairing the inhibitory effects of lenvatinib against CCA. In addition, the AKT inhibitor, MK-2206, reinforced the lenvatinib-induced CCA inhibition. Notably, the in vivo experiment confirmed that the subcutaneous tumorigenicity of CCA cells in nude mice was weakened by lenvatinib. Lenvatinib markedly downregulated the expression of FGF19, p-AKT, Ki-67, vimentin, and VEGF in the xenograft tumor tissues. Collectively, these findings demonstrated that lenvatinib inhibits CCA progression by targeting the FGF19/PI3K/AKT signaling pathway. The present study provides novel experimental evidence for the potential clinical application of lenvatinib in CCA, which also highlights the promising role of targeting FGF19 in combined therapeutic approaches for CCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesPhenylurea CompoundsProto-Oncogene Proteins c-aktSignal TransductionPhosphatidylinositol 3-KinasesCholangiocarcinomaFibroblast Growth FactorsBile Duct NeoplasmsAntineoplastic AgentsHumansAnimalsCell Line, TumorMiceMice, NudeCell ProliferationApoptosisCell MovementXenograft Model Antitumor AssaysDisease ProgressionMice, Inbred BALB CGene Expression Regulation, NeoplasticMale

Stichwörter der Autor:innen

CholangiocarcinomaFGF19LenvatinibPI3K/AKT signaling pathwayTargeted therapy

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesFibroblast Growth FactorsFGF19 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, Guangdong, China.
  • Department of Hepatopancreatobiliary Surgery, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, 516621, Guangdong, China.
  • Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, Guangdong, China.
  • Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
  • Department of Breast Surgery, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, 516621, Guangdong, China.
  • Department of Hepatobiliary Surgery, Health Science Center, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, Guangdong, China.

Förderung

  • Guangzhou Municipal Science and Technology Project
  • National Natural Science Foundation of China
  • Natural Science Foundation of Hunan Province
  • Health Commission of Hunan Province
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Wei, Y., Yang, L., Tang, C., Zhuang, H., Chen, X., Ma, X., Deng, X., Chen, Y., Tan, W., & Shang, C. (2025). Lenvatinib inhibits cholangiocarcinoma progression by targeting the FGF19/PI3K/AKT signaling pathway. Apoptosis, 30(1-2), 185-196. https://doi.org/10.1007/s10495-024-02028-2

Vancouver

Wei Y, Yang L, Tang C, Zhuang H, Chen X, Ma X, et al. Lenvatinib inhibits cholangiocarcinoma progression by targeting the FGF19/PI3K/AKT signaling pathway. Apoptosis. 2025;30(1-2):185-196. doi:10.1007/s10495-024-02028-2

BibTeX
@article{Wei2025,
  author = {Wei, Yingcheng and Yang, Lei and Tang, Chenwei and Zhuang, Hongkai and Chen, Xinming and Ma, Xiaowu and Deng, Xuesong and Chen, Yajin and Tan, Wenliang and Shang, Changzhen},
  title = {Lenvatinib inhibits cholangiocarcinoma progression by targeting the FGF19/PI3K/AKT signaling pathway},
  journal = {Apoptosis},
  year = {2025},
  volume = {30},
  number = {1-2},
  pages = {185--196},
  doi = {10.1007/s10495-024-02028-2}
}
Kostenlos starten →